In parallel to our small molecule drug conjugates (SMDCs) program, Philochem has developed and patented a number of radiolabeled ligands for cancer imaging. These radiolabelled ligands consist of a high affinity binder of tumor-associated antigens, conjugated to different chelating moieties for the functionalization with several radioisotopes. PHC-102, a proprietary 99mTc-radiolabelled ligand of Carbonic Anhydrase IX (CAIX, a validated marker of solid tumors), will soon enter in Phase I clinical trial for the imaging of clear cell renal cell carcinoma and hypoxia.
Krall et al. (2016) J. Nucl. Med. 57:943-9;
Cazzamalli et al.(2016) Mol Cancer Ther. [Epub ahead of print];
Minn et al. (2016) Oncotarget. [Epub ahead of print];
Yang et al. (2015) Oncotarget. 6:33733-42